23 June 2022 - EMA has recommended granting a marketing authorisation for COVID-19 Vaccine (inactivated, adjuvanted) Valneva for use in ...
23 June 2022 - EMA’s CHMP has recommended granting an extension of indication for the COVID-19 vaccine Nuvaxovid to include use ...
23 June 2022 - To 19 June 2022, the TGA has received 581 reports which have been assessed as likely to ...
22 June 2022 - The Australian Government today launched an $11 million six-week campaign to encourage people to get vaccinated for ...
22 June 2022 - Clinical data supporting approval demonstrated non-inferior immune responses for all serotypes shared with PCV13 following a four ...
17 June 2022 - Speaking about the waiver, EFPIA Director General, Nathalie Moll said. “The decision is a serious retrograde step ...
20 June 2022 - The decision to waive intellectual property protections for COVID-19 vaccines is fundamentally flawed and will have ...
17 June 2022 - EMA has started a rolling review for a version of Spikevax adapted to provide better protection ...
17 June 2022 - mRNA-1273 has been administered to millions of children and adolescents over the age of 6 worldwide, ...
17 June 2022 - In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 vaccine elicited a strong immune response in this ...
16 June 2022 - To 12 June 2022, the TGA has received 584 reports which have been assessed as likely to ...
15 June 2022 - EMA has started a rolling review for a version of Comirnaty adapted to provide better protection ...
13 June 2022 - In Australia, Nuvaxovid is the first protein-based COVID-19 vaccine registered for use as a booster regardless ...
14 June 2022 - Vaccinating the world remains a priority and proposals to weaken the intellectual property for COVID-19 vaccines ...
9 June 2022 - To 5 June 2022, the TGA has received 577 reports which have been assessed as likely to ...